Sunday, May 3, 2026
Today's Print

Tag: endocrine therapy

Novartis ribociclib Phase III NATALEE trial meets primary endpoint at interim analysis

Demonstrating clinically meaningful benefit in broad population of patients with early breast cancer Ribociclib plus endocrine therapy (ET) significantly reduced the risk of disease recurrence...
- Advertisement -spot_img
- Advertisement -spot_img